Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Call for improved design and reporting in soft tissue sarcoma studies: A systematic review and meta-analysis of chemotherapy and survival outcomes in resectable STS. J Surg Oncol 2019 Jun;119(7):824-835

Date

02/10/2019

Pubmed ID

30737793

DOI

10.1002/jso.25401

Scopus ID

2-s2.0-85061235303 (requires institutional sign-in at Scopus site)   12 Citations

Abstract

New evidence and systemic therapies demand an updated analysis of chemotherapy for soft tissue sarcoma. We completed a meta-analysis of chemotherapy in localized STS, assessing OS, PFS, and local and distant recurrence (local recurrence-free survival [LRFS] and distant recurrence-free survival [DRFS]). Ten studies, totaling 3157 patients, were included. A pooled analysis for 5-year OS, progression-free survival, LRFS, and DRFS showed no benefit of chemotherapy over locoregional therapy alone for all-comers or site-specific STS. We make recommendations to improve outcome reporting and quality indices.

Author List

Istl AC, Ruck JM, Morris CD, Levin AS, Meyer CF, Johnston FM

Author

Alexandra C. Istl MD, MPH Assistant Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Chemotherapy, Adjuvant
Humans
Neoadjuvant Therapy
Randomized Controlled Trials as Topic
Sarcoma
Survival Rate